

20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT  
SEQUENCE LISTING

<110> Fusion Pharmaceuticals, Inc.

<120> RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION  
THERAPY

<130> FPI-005

<140> PCT/IB2019/001342

<141> 2019-12-03

<150> 62/774847

<151> 2018-12-03

<160> 24

<170> PatentIn version 3.5

<210> 1

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR-L1 of AVE1642

<400> 1

Arg Ser Ser Gln Ser Ile Val His Ser Asn Val Asn Thr Tyr Leu Glu  
1 5 10 15

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR-L2 of AVE1642

<400> 2

Lys Val Ser Asn Arg Phe Ser  
1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

&lt;220&gt;

&lt;223&gt; CDR-L3 of AVE1642

&lt;400&gt; 3

Phe Gln Gly Ser His Val Pro Pro Thr  
1 5

&lt;210&gt; 4

&lt;211&gt; 150

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Light chain variable region of AVE1642

&lt;400&gt; 4

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
1 5 10 15Asp Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser  
20 25 30Asn Val Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
35 40 45Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro  
50 55 60Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Arg Ile  
65 70 75 80Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly  
85 90 95Ser His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105 110Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu  
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe

Page 2

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

130

135

140

Tyr Pro Arg Glu Ala Lys  
145 150

<210> 5  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR-H1 of AVE1642

<400> 5

Ser Tyr Trp Met His  
1 5

<210> 6  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR-H2 of AVE1642

<400> 6

Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Gln Lys Phe  
1 5 10 15

Gln Gly

<210> 7  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR-H3 for AVE1642

<400> 7

Gly Arg Pro Asp Tyr Tyr Gly Ser Ser Lys Trp Tyr Phe Asp Val  
1 5 10 15

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

&lt;210&gt; 8

&lt;211&gt; 150

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Heavy chain variable region of AVE1642

&lt;400&gt; 8

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Gln Lys Phe  
50 55 60

Gln Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Phe  
85 90 95

Ala Arg Gly Arg Pro Asp Tyr Tyr Gly Ser Ser Lys Trp Tyr Phe Asp  
100 105 110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys  
115 120 125

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly  
130 135 140

Gly Thr Ala Ala Leu Gly  
145 150

&lt;210&gt; 9

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Epitope for endosialin antibody

&lt;400&gt; 9

Ser Arg Asp His Gln Ile Pro Val Ile Ala Ala Asn  
1 5 10

&lt;210&gt; 10

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; CDR-H1 for endosialin antibody

&lt;400&gt; 10

Gly Tyr Gly Val Asn  
1 5

&lt;210&gt; 11

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; CDR-H1 for endosialin antibody

&lt;400&gt; 11

Gly Phe Ser Leu Thr Gly Tyr Gly Val Asn  
1 5 10

&lt;210&gt; 12

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; CDR-H2 for endosialin antibody

&lt;400&gt; 12

Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys Ser

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

1 5 10 15

<210> 13  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR-H3 for endosialin antibody

<400> 13

Gly Gly Tyr Gly Ala Met Asp Tyr  
1 5

<210> 14  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR-L1 for endosialin antibody

<400> 14

His Ala Ser Gln Asn Ile Asn Val Trp Leu Thr  
1 5 10

<210> 15  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR-L2 for endosialin antibody

<400> 15

Lys Ala Ser Asn Leu His Thr  
1 5

<210> 16  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR-L3 for endosialin antibody

Page 6

## 20200319 FPI-005\_Sequence\_Listing\_ST25.TXT

&lt;400&gt; 16

Gln Gln Gly Gln Ser Tyr Pro Trp Thr  
1 5

&lt;210&gt; 17

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized VH1 for endosialin antibody

&lt;400&gt; 17

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu  
1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr  
20 25 30Gly Val Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys  
50 55 60Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val  
100 105 110Thr Val Ser Ser  
115

&lt;210&gt; 18

&lt;211&gt; 116

&lt;212&gt; PRT

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized VH2 for endosialin antibody

&lt;400&gt; 18

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu  
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr  
 20 25 30

Gly Val Asn Trp Ile Arg Gln Pro Pro Glu Lys Gly Leu Glu Trp Ile  
 35 40 45

Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys  
 50 55 60

Ser Arg Val Asn Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val  
 100 105 110

Thr Val Ser Ser  
 115

&lt;210&gt; 19

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized VH3 for endosialin antibody

&lt;400&gt; 19

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu  
 1 5 10 15

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr  
20 25 30

Gly Val Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val  
100 105 110

Thr Val Ser Ser  
115

<210> 20  
<211> 116  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Humanized VH4 for endosialin antibody

<400> 20

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr  
20 25 30

Gly Val Asn Trp Ile Arg Gln Pro Pro Glu Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

50

55

60

Ser Arg Val Asn Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val  
100 105 110

Thr Val Ser Ser  
115

<210> 21  
<211> 107  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Humanized VL1 for endosialin antibody

<400> 21

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp  
20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp  
85 90 95

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 22  
<211> 107  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Humanized VL2 for endosialin antibody

<400> 22

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp  
20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 23  
<211> 107  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Humanized VL3 for endosialin antibody

<400> 23

## 20200319 FPI-005\_Sequenc\_Listing\_ST25.TXT

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp  
20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 24

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized VL4 for endosialin antibody

<400> 24

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp  
20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile  
35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly

## 20200319 FPI-005\_Sequence\_Listing\_ST25.TXT

50

55

60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105